Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385214 · ClinicalTrials.gov registry record · NA
MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
A NA study of Cutaneous Melanoma by AJCC V7 Stage, sponsored by Melanoma and Skin Cancer Trials Limited.
- Active
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT02385214 is a NA study of Cutaneous Melanoma by AJCC V7 Stage that is active but no longer recruiting, run by Melanoma and Skin Cancer Trials Limited. The registered enrollment target is 400 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT02385214, a NA study of Cutaneous Melanoma by AJCC V7 Stage, is active but no longer recruiting, sponsored by Melanoma and Skin Cancer Trials Limited.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas \>=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients
Conditions Studied
Interventions
- PROCEDURE Wide Local Excision = 1cm Margin
- PROCEDURE Wide Local Excision = 2cm Margin
Study Locations (20)
Other
- Sunnybrook Health Sciences Centre - Toronto
- Sahlgrenska University Hospital - Gothenburg
- North Bristol NHS Trust - Bristol
- Cambridge University Hospitals NHS Foundation Trust - Cambridge
- Royal Devon and Exeter NHS Foundation Trust - Exeter
- St. James University Hospital - Leeds
- Royal Free London NHS Foundation Trust - London
- Imperial College Healthcare NHS Trust - London
- Norfolk and Norwich University Hospital - Norwich
England
- Hull and East Yorkshire Hospitals NHS Trust - Hull
- Guy's and St Thomas' Hospital NHS Trust - London
- The Christie NHS Foundation Trust - Manchester
Victoria
- Peter MacCallum Cancer Centre Division of Cancer Surgery - Melbourne
- Alfred Hospital - Melbourne
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
New South Wales
- Melanoma Institute Australia - Poche Centre - North Sydney
Queensland
- Gold Coast Melanom Clinic - Coolangatta
Essex
- Mid Essex Hospital Services NHS Trust - Broomfield
Mersyside
- St Helens & Knowsley NHS Trust - St Helens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2015-01-03 |
| Est. Completion | 2026-08-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02385214
The ClinicalTrials.gov registry entry for NCT02385214 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melanoma and Skin Cancer Trials Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Melanoma by AJCC V7 Stage appearing as the primary indexed condition, and to 2 interventions - of which Wide Local Excision = 1cm Margin is the first listed.
NCT02385214 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, England, Victoria.
Frequently Asked Questions
What is clinical trial NCT02385214 about?
NCT02385214 is a clinical study titled "MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma". Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for ...
What is the current status of trial NCT02385214?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2015-01-03. Estimated completion is 2026-08-05.
What conditions does trial NCT02385214 study?
This clinical trial studies the following conditions: Cutaneous Melanoma by AJCC V7 Stage.
What interventions are being tested in trial NCT02385214?
The interventions under investigation include: Wide Local Excision = 1cm Margin (PROCEDURE), Wide Local Excision = 2cm Margin (PROCEDURE).
Who is sponsoring clinical trial NCT02385214?
This trial is sponsored by Melanoma and Skin Cancer Trials Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02385214 being conducted?
This trial has 20 study locations across Pennsylvania, New South Wales, Queensland, Victoria, England. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma by AJCC V7 Stage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.